Dimensional Fund Advisors LP Acquires 286,181 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Dimensional Fund Advisors LP boosted its stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 101.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 569,357 shares of the company's stock after acquiring an additional 286,181 shares during the period. Dimensional Fund Advisors LP owned 0.81% of Nkarta worth $1,417,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Invesco Ltd. bought a new position in shares of Nkarta in the 4th quarter worth about $30,000. Sequoia Financial Advisors LLC purchased a new stake in Nkarta in the fourth quarter worth about $31,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Nkarta during the fourth quarter valued at approximately $37,000. Catalina Capital Group LLC lifted its holdings in shares of Nkarta by 57.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock valued at $47,000 after purchasing an additional 6,867 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Nkarta during the fourth quarter valued at approximately $57,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Nkarta Stock Down 5.6%

Shares of NASDAQ NKTX opened at $1.70 on Thursday. The firm's 50-day moving average price is $1.79 and its 200-day moving average price is $2.17. Nkarta, Inc. has a 52-week low of $1.31 and a 52-week high of $8.23. The company has a market cap of $120.63 million, a PE ratio of -0.90 and a beta of 0.81.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. As a group, equities research analysts anticipate that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NKTX has been the subject of a number of recent research reports. Stifel Nicolaus dropped their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 27th. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Nkarta in a research report on Thursday, March 27th. Needham & Company LLC decreased their target price on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, May 15th. Finally, William Blair reiterated a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $14.67.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.